Biomarkers discovered in Parkinson's disease.

A new method enables the detection of the onset of Parkinson's disease before the onset of brain damage and symptoms such as tremors. A protein in the brain water can indicate early on Parkinson's. Experts describe the procedure as a "game changer" for the diagnosis, research and treatment of Parkinson's. The findings are expected to have implications for new therapies.

For me, who myself have Parkinson's disease, this new study is a real breakthrough for Parkinson's diagnosis and therapy development. It is really encouraging that it may now be possible to detect the disease before the brain becomes damaged and the typical symptoms such as tremors appear.

Until now, Parkinson's has often been difficult to diagnose because the disease was often not diagnosed until significant damage had already occurred in the brain. But now, with this test, which can detect the misfolded protein alpha-synuclein in the cerebrospinal fluid, an early diagnosis could be made possible. This protein is a key feature of Parkinson's and may help improve the development of therapies.

It is also interesting that genetic risk factors such as certain gene variants can influence the risk of developing the disease. As someone with Parkinson's, it is important for me to understand how different factors can contribute to the development of the disease.

It is particularly impressive that the test was already able to detect the protein in people with pre-Parkinson's disease, in whom no changes in the nerve cells in the brain could be detected. This shows that alpha-synuclein could be a very early indication of the onset of the disease.

The study gives hope for the future of Parkinson's diagnosis and therapy development. It's a big step forward and I'm sure these discoveries will lead to new and improved therapies in the years to come.